MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ -- MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary ...
Introduction: The positive outcomes of the COMPASS trial raise questions about the proportion of patients who could benefit from additional therapy with rivaroxaban in real-world practice. Objectives: ...
The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of ...
COMPASS-CAD started enrolling patients in November 2024 at Penn Medicine and has expanded to other sites. In COMPASS-CAD, patients classified as intermediate or borderline risk based on traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results